Ratings Henan Lingrui Pharmaceutical Co., Ltd.

Equities

600285

CNE000001501

End-of-day quote Shanghai S.E. Other stock markets 2024-09-11			5-day change	1st Jan Change
20.09 ^CNY	-7.46%		-14.58%	+17.42%

08-12	Henan Lingrui Pharmaceutical Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2024	CI
05-13	Lingrui Pharma Gets Green Light to Market Type 2 Diabetes Drug	MT

Summary: Henan Lingrui Pharmaceutical Co., Ltd.

The company has strong fundamentals. More than 70% of companies have a lower mix of growth, profitability, debt and visibility.

Highlights: Henan Lingrui Pharmaceutical Co., Ltd.

Margins returned by the company are among the highest on the stock exchange list. Its core activity clears big profits.
This company will be of major interest to investors in search of a high dividend stock.
For the past year, analysts covering the stock have been revising their EPS expectations upwards in a significant manner.
Analysts have a positive opinion on this stock. Average consensus recommends overweighting or purchasing the stock.
The difference between current prices and the average target price is rather important and implies a significant appreciation potential for the stock.
Analyst opinion has improved significantly over the past four months.
There is high visibility into the group's activities for the coming years. Outlooks on future revenues from analysts covering the equity remain similar. Such hardly dispersed estimates support highly predictable sales for the current and upcoming fiscal years.
Analysts' price targets are all relatively close, reflecting good visibility on the company's valuation.

Weaknesses: Henan Lingrui Pharmaceutical Co., Ltd.

The company appears highly valued given the size of its balance sheet.
For the last twelve months, sales expectations have been significantly downgraded, which means that less important sales volumes are expected for the current fiscal year over the previous period.
Over the past four months, analysts' average price target has been revised downwards significantly.
Over the past twelve months, analysts' consensus has been significantly revised downwards.

Ratings Chart: Henan Lingrui Pharmaceutical Co., Ltd.

Source: Surperformance

Sector Comparison:

Add to a list Add to a list 0 selected To use this feature you must be a member Log in Sign up	Composite Valuation	Capi. ($)
HENAN LINGRUI PHARMACEUTICAL CO., LTD.		1.59B
DONG-E-E-JIAO CO.,LTD.		4.19B
SHIJIAZHUANG YILING PHARMACEUTICAL CO., LTD.		3.52B
TASLY PHARMACEUTICAL GROUP CO., LTD		2.9B
TIANJIN PHARMACEUTICAL DA REN TANG GROUP CORPORATION LIMITED	-	2.57B
TIANJIN CHASE SUN PHARMACEUTICAL CO.,LTD	-	1.34B
PT INDUSTRI JAMU DAN FARMASI SIDO MUNCUL TBK		1.32B
Average		2.49B
Weighted average by Cap.

See all sector ratings

Investor Rating

Trading Rating

ESG Refinitiv

Financials

Sales growth

Earnings Growth

EBITDA / Sales

Profitability

Finances

Valuation

P/E ratio

EV / Sales

Price to Book

Price to Free Cash Flow

Yield

Momentum

1 year Revenue revision

4 months Revenue revision

7 days Revenue revision

1 year EPS revision

4 months EPS revision

Consensus

Analyst Opinion

Potential Price Target

4m Target Price Revision

4m Revision of opinion

12m Revision of opinion

Business Predictability

Analyst Coverage

Divergence of Estimates

Divergence of analysts' opinions

Divergence of Target Price

Earnings quality

Technical analysis

ST Timing

MT Timing

LT Timing

RSI

Bollinger Spread

Unusual volumes